The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ted Tenthoff - Piper Sandler Companies - Analyst
: Hi, everybody. Thanks so much to the doctors for the time and their perspective today. I think I have a question both for the company and also for
the doc. So sure I've asked you guys, you have learned this before, but when it comes to packaging, how do you envision delivering the etripamil
nasal units?
And to the doctors, how do you envision real world use? So is this something they would kind of carry around with them and have two in case they
needed it? Do you think this would actually be used by your PSVT patients? Thanks, guys.
Question: Dennis Ding - Jefferies LLC - Analyst
: Hi, good morning. Thanks for taking my questions and thanks to the doctors for their great comments this morning. So further doctors, maybe
comment around the willingness for your patients to use etripamil for every episode that they get and maybe their willingness to pay the co-pay
each time. I'm just wondering would some patients kind of waited out given some of these episodes self-resolved and how would that co-pay
situation, I guess potentially impact that? Thank you very much.
Question: Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
: Thanks. Good morning. A couple of questions for the KOLs. First, I'm wondering what proportion of PSVT patients who believe would be eligible
for treatment at the time of approval? And of these, what proportion consists of those patients that may be readily identified? And to what extent
do you believe having etripamil treatment, if it's approved, may improve diagnosis or identification of new patients?
So in other words, what we're trying to better understand is how large an addressable patient population is today and how it may trend in the
future if etripamil is approved? And then secondly, I am wondering if you can discuss the number of PSVT episodes patients experienced on average
per year and of those for the patients where you see etripamil is appropriate, how many of those episodes would actually have been treated with
etripamil on average annually if it's approved? Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 20, 2024 / 12:00PM, MIST.OQ - Milestone Pharmaceuticals Inc KOL Series
|
